A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase

Trial Profile

A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Entinostat (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ENCORE 602
  • Sponsors Syndax Pharmaceuticals
  • Most Recent Events

    • 10 Aug 2017 According to a Syndax Pharmaceuticals media release, this trial is expected to complete enrollment in the phase 2 portion by the end of the fourth quarter.
    • 02 Mar 2017 According to a Syndax Pharmaceuticals media release, Phase 1b portion has completed enrollment and, following a thorough review of the safety data, the Phase 2 portion of the trial was recently initiated.
    • 22 Dec 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top